Gonadotropin-releasing hormone agonists

Craig A. Winkel, Winkel CA
Postgraduate medicine · 1994 · vol. 95(6) , pp. 111–118 · doi:10.1080/00325481.1994.11945846 · PMID:29211615 · W2773032415
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This article reviews the use of gonadotropin-releasing hormone agonists for treating endometriosis, advanced prostate cancer, and precocious puberty.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Preview Gonadotropin-releasing hormone (GnRH) agonists will have a significant impact on the practice of medicine in the 1990s. These agents will likely be given to increasing numbers of patients, and primary care physicians themselves may wish to prescribe the drugs when appropriate. This article describes the use of GnRH agonists in the treatment of endometriosis, advanced prostate cancer, and precocious puberty.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Cited by (2)

Source provenance

europepmc
last seen: 2026-09-09T06:15:24.302764+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:24.284338+00:00
unpaywall
last seen: 2026-09-09T06:31:01.691765+00:00
License: CC0 · commercial use OK